Ezéchiel Ngoufack Jagni Semengue

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals

Alex Durand Nka, Yagaï Bouba, Georges Této et al. · Journal of Antimicrobial Chemotherapy · 2022 · 25 citations

Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings

Ezéchiel Ngoufack Jagni Semengue, Daniele Armenia, Seth Inzaule et al. · Journal of Antimicrobial Chemotherapy · 2021 · 22 citations · Full text

Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics

Joseph Fokam, Alex Durand Nka, Flore Yollande Mamgue Dzukam et al. · Medicine · 2023 · 22 citations · Full text

Antiviral Drug, Covid-19, Pediatric Epidemiology +20

Correlation between the immuno-virological response and the nutritional profile of treatment-experienced HIV-infected patients in the East region of Cameroon

Aissatou Abba, Joseph Fokam, Rachel Simo Kamgaing et al. · PLoS ONE · 2021 · 21 citations · Full text

Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model

Ezéchiel Ngoufack Jagni Semengue, Joseph Fokam, Naomi-Karell Etame et al. · Viruses · 2022 · 20 citations · Full text

Hiv Viral Load, Immunodeficiencies, Antiviral Drug +17